The valley where the Tigris and Euphrates Rivers flows down through what is now modern-day Iraq is literally a cradle of Civilization. After all, the world’s first writing occurs here in the form of cuneiform—the language of ancient Mesopotamia. Iraq’s University of Baghdad is the Arab’s world’s second largest university, and by some accounts got it’s start in 1067 AD as Abu-Haneefa. Regardless, its modern form materialized as the College of Law in 1908, and a College of Medicine launched in 1927. In 2020, the university was listed in the Times Higher Education World University Rankings. Recently the College of Medicine’s research arm launched a clinical trial to assess the safety and efficacy of adjuvant use of Ivermectin in Covid-19 patients with Pneumonia.
Is there something to this Ivermectin and COVID-19?
TrialSite News has been monitoring the use of Ivermectin around the globe—starting with the University of Monash findings in a laboratory cell culture experiment. Then MedinCell, a French biotech company, commenced an Ivermectin research program centering on COVID-19; in parallel, a physician in Broward County Florida received official approval from a local health board to use an Ivermectin combination therapy. Down in South America, a Brazilian University studies the use of Ivermectin on COVID-19 patients, then skipping over the Atlantic Ocean to Northern Africa Egypt where University of Tanta conducts three studies on Ivermectin. Now the University of Baghdad.
The University of Baghdad Study?
This influential Middle East institution of higher learning is comparing in this Phase I study the efficacy and safety of adjuvant use of Ivermectin in COVID-19 patients with pneumonia using Ivermectin 0.2 mg/kg (12 mg adult dose) single dose at once repeated after 1 week combined with hydroxychloroquine 400 mg daily compared to Hydroxychloroquine, plus placebo single one dose repeated after 1 week. They will enroll 50 participants.
Put another way, they want to see if adding Ivermectin to Hydroxychloroquine makes a difference to those infected with COVID-19. The study started April 18, 2020 and runs through until August 2020.
The study’s primary outcome involves the investigators looking at number of cured patients in two weeks and involves the number of patients cured as assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID-19 (PCR) in addition to chest x-rays. They are looking at secondary outcome measures including number of participants with treatment-related adverse events within the first two weeks.
Faiq I Gorial, Professor
Award I Rasheed, Arab Board for Health Specialization in Iraq.